www.fdanews.com/articles/201281-eli-lillys-covid-19-antibody-cocktail-receives-ema-review
Eli Lilly’s COVID-19 Antibody Cocktail Receives EMA Review
February 9, 2021
The European Medicines Agency (EMA) is reviewing Eli Lilly’s antibody cocktail as a potential treatment for COVID-19 patients who don’t require supplemental oxygen and are at high risk of progressing to severe disease.
Preliminary study data on Lilly’s bamlanivimab/etesevimab cocktail showed the combination treatment reduced viral load as well as COVID-19-associated medical visits and hospitalizations and the EMA’s human medicines committee is considering a recommendation for conditional marketing authorization.
Results from a phase 3 study showed the antibody cocktail reduced the risk of COVID-19 hospitalization or death by 70 percent.